Market Access Why ‘reduce, reuse, and recycle' medicine is the future The ultimate raison d’être of any medicine is to benefit patients.
Patients UK-wide whole genome sequencing for newborns is feasible - b... Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year ann
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
